Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
复制标题
DOI：
10.3389/fonc.2022.898964
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Zheng, Chuansheng
中科院分区：
文献类型：
--
作者：
Ouyang, Tao;Kan, Xuefeng;Zheng, Chuansheng
肝细胞癌（HCC）是癌症死亡的重要原因，被认为是世界上第三大致命癌症。肝切除术、肝移植和消融治疗被认为是早期 HCC 的治疗方法。经动脉化疗栓塞是中期 HCC 的首选治疗方法。建议对晚期 HCC 进行全身治疗。十多年来，索拉非尼和仑伐替尼一直被用作晚期 HCC 的一线治疗。由于免疫治疗在黑色素瘤和肺癌方面取得了巨大成功，一些基于免疫的治疗方法，如免疫检查点抑制剂（ICIs），已被应用于HCC的治疗。抗程序性细胞死亡蛋白 1 (PD1) 抗体，包括纳武单抗和派姆单抗，已获得美国食品和药物管理局批准用于接受过索拉非尼治疗的患者。此外，由于 3 期试验取得的持久抗肿瘤反应结果，atezolizumab 与贝伐珠单抗联合用药现已成为晚期 HCC 的标准疗法。最近，有很多涉及ICIs的临床试验，作为单一疗法或联合疗法，与酪氨酸激酶抑制剂、抗血管生成药物、细胞毒药物和局部治疗一起，为晚期HCC提供了有希望的结果。因此，本综述总结了 ICI 对单药治疗或联合治疗的 HCC 患者的作用。 ICI 单一疗法和联合疗法的成功和失败为 HCC 治疗提供了先进的见解，并为提高 HCC 治疗效果开辟了新途径。
Hepatocellular carcinoma (HCC) is an important cause of cancer death and is considered the 3rd most lethal around the world. Hepatectomy, liver transplantation, and ablation therapy are considered curative treatments for early-stage HCC. Transarterial chemoembolization is the preferred therapy for intermediate stage HCC. Ssystemic therapy is recommended for advanced HCC. For more than a decade, sorafenib and lenvatinib were used as the first-line treatment for the advanced HCC. For the great success of immunotherapy in melanoma and lung cancer, some immune-based treatments, such as immune checkpoint inhibitors (ICIs), have been applied in the treatment of HCC. The anti-programmed cell death protein 1 (PD1) antibodies, including nivolumab and pembrolizumab, have been approved by the Food and Drug Administration for sorafenib-pretreated patients. Moreover, due to the results of durable antitumor responses attained from the phase 3 trials, atezolizumab in combination with bevacizumab is now the standard therapy for advanced HCC. Recently, there are a lot of clinical trials involving the ICIs, as monotherapy or combination therapy, with tyrosine kinase inhibitors, antiangiogenic drugs, cytotoxic agents, and locoregional treatments, providing a promising outcome for advanced HCC. Thus, this review summarized the role of ICIs for HCC patients with monotherapy or combination therapy. The success and failures of monotherapy and combination therapy involving ICIs have provided advanced insights into HCC treatment and led to novel avenues to improve therapy efficacy in HCC.
登录
查看更多内容
影响因子：
5.1
作者：
Choi, Won-Mook;Choi, Jonggi;Kim, Kang Mo
通讯作者：
Kim, Kang Mo
多重定量分析LAG-3、FGL1、PD-L1和CD8 T细胞在肝细胞癌中的表达及临床意义
影响因子：
7.4
作者：
Guo, Mengzhou;Yuan, Feifei;Xia, Jinglin
通讯作者：
Xia, Jinglin
影响因子：
45.3
作者：
Finn, Richard S.;Ikeda, Masafumi;Llovet, Josep M.
通讯作者：
Llovet, Josep M.
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
PD-L1 的过度表达与人类肝细胞癌的肿瘤侵袭性和术后复发显着相关。
影响因子：
11.5
作者：
Gao, Qiang;Wang, Xiao-Ying;Fan, Jia
通讯作者：
Fan, Jia